Citigroup Maintains Neutral on Ovid Therapeutics, Lowers Price Target to $3.5
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Yigal Nochomovitz has maintained a Neutral rating on Ovid Therapeutics (NASDAQ:OVID) and lowered the price target from $4 to $3.5.

May 07, 2024 | 5:42 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Citigroup has maintained a Neutral rating on Ovid Therapeutics and reduced the price target from $4 to $3.5.
The reduction in price target by Citigroup, a major financial institution, could lead to a negative short-term sentiment among investors, potentially causing a decrease in OVID's stock price. The Neutral rating suggests no significant positive catalysts in the near term to counterbalance the lowered price target.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100